Jim Wassil Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 8,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $83.66, for a total transaction of $669,280.00. Following the sale, the chief operating officer now owns 205,695 shares in the company, valued at $17,208,443.70. This trade represents a 3.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Jim Wassil also recently made the following trade(s):

• On Monday, December 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $92.49, for a total transaction of $739,920.00.
• On Friday, November 1st, Jim Wassil sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $106.80, for a total transaction of $854,400.00.

Vaxcyte Trading Up 1.9 %

NASDAQ PCVX opened at $84.86 on Friday. Vaxcyte, Inc. has a 12 month low of $53.83 and a 12 month high of $121.06. The stock has a 50 day moving average of $92.63 and a 200-day moving average of $93.07. The company has a market cap of $10.58 billion, a PE ratio of -18.45 and a beta of 0.94.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter last year, the firm posted ($0.91) earnings per share. As a group, sell-side analysts predict that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PCVX has been the topic of several recent research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Needham & Company LLC reissued a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a research report on Wednesday, November 6th. Mizuho upped their price target on Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. Finally, The Goldman Sachs Group started coverage on shares of Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 price objective on the stock. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $145.71.

Hedge Funds Weigh In On Vaxcyte

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Riverview Trust Co acquired a new stake in shares of Vaxcyte in the third quarter valued at approximately $27,000. Blue Trust Inc. raised its stake in Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after acquiring an additional 93 shares during the period. Quest Partners LLC acquired a new stake in Vaxcyte during the 2nd quarter valued at $70,000. Meeder Asset Management Inc. boosted its position in Vaxcyte by 1,007.9% during the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock worth $80,000 after purchasing an additional 635 shares during the period. Finally, Nomura Asset Management Co. Ltd. acquired a new position in shares of Vaxcyte in the third quarter valued at $92,000. Institutional investors own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.